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Abstract
Introduction:  Recently,  it  has  been  suggested  an  association  between  red  cell distribution  width
(RDW) and  Crohn’s  disease  activity  index  (CDAI),  but  its  use  is not  yet  performed  in daily  clinical
practice.
Objectives:  To  determine  whether  RDW  can  be used  as  a  marker  of  Crohn’s  disease  (CD)  activity.
Methods: This  was  a  cross-sectional  study  including  patients  with  CD,  observed  consecutively
in an  outpatient  setting  between  January  1st  and  September  30th  2013.  Blood  cell  indices,
erythrocyte  sedimentation  rate  (ESR),  and  C-reactive  protein  were  measured.  CD activity  was
determined by  CDAI  (active  disease  if CDAI ≥ 150).  Associations  were  analyzed  using  logistic
regression  (SPSS  version  20).
Results:  119 patients  (56%  female)  were  included  in  the  study  with  a  mean  age  of  47  years
(SD 15.2).  Twenty  patients  (17%)  had  active  disease.  The  median  RDW  was  14.0  (13--15).  There
was an  association  between  RDW  and disease  activity  (p =  0.044).  After  adjustment  for  age  and
gender,  this  association  remained  consistent  (OR  1.20,  95%  CI 1.03--1.39,  p  =  0.016).  It  was  also
found that  the  association  between  RDW  and  disease  activity  was  independent  of  hemoglobin
and ESR  (OR  1.36,  95%  CI 1.08--1.72,  p  = 0.01)  and of  biologic  therapy  (OR  1.19,  95%  CI  1.03--1.37,
p =  0.017).  A RDW  cutoff  of  16%  had  a  specificity  and  negative  predictive  value  for  CDAI  ≥ 150
of 88%  and  86%,  respectively.
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Conclusion:  In  this study,  RDW  proved  to  be  an  independent  and  relatively  specific  marker  of
CD activity.  These  results  may  contribute  to  the  implementation  of  this  simple  parameter,  in
clinical practice,  aiming  to  help  therapeutic  decisions.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.
This is an  open  access  article  under  the  CC BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
PALAVRAS-CHAVE
Doenc¸a de Crohn;
Índices  de  Eritrócitos
A  Amplitude  de  Distribuic¸ão  dos Glóbulos  Vermelhos  (RDW)  Pode  Ser  Considerado
Como  um  Marcador  da  Atividade  da  Doenc¸a de  Crohn?
Resumo
Introduc¸ão: Recentemente,  tem  vindo  a  ser  sugerida  uma  associac¸ão  entre  o  valor  de  RDW  e
a atividade  da doenc¸a  de Crohn  (DC),  mas a  sua  utilizac¸ão  não  está  ainda  implementada  na
prática clínica  diária.
Objetivos:  Determinar  se  o  RDW  pode  ser  utilizado  como  marcador  de atividade  da  DC.
Métodos:  Estudo  transversal,  em  doentes  com  DC,  observados  consecutivamente  em  consulta
de Doenc¸a  Inflamatória  Intestinal,  entre  1 de  janeiro  e 30  de  setembro  de 2013.  Analisaram-se
índices do  hemograma,  proteína  C reativa  e  velocidade  de sedimentac¸ão.  A  gravidade  da  doenc¸a
foi avaliada  pelo  Crohn’s  disease  activity  index  (doenc¸a ativa  se  CDAI≥150).  As  associac¸ões
foram  estudadas  usando  a  regressão  logística  (SPSS  Statistics  V20).
Resultados:  Incluídos  119 doentes  (56%  do  sexo  feminino),  com  idade  média  de 47  anos  (DP  15,2
anos). Vinte  doentes  (17%)  tinham  doenc¸a  ativa.  O  valor  do RDW  mediano  foi  14,0%  (13-15).
Verificou-se  uma  associac¸ão  entre  RDW  e atividade  da  doenc¸a (p  = 0,044).  Após  ajuste  para  a
idade e o sexo,  esta  associac¸ão  manteve-se  consistente  (OR  1,20;  95%  CI  1,03-1,39;  p  =  0,016).
Verificou-se  ainda  que  a  associac¸ão  do valor  do  RDW  com  a  atividade  da  doenc¸a  foi  independente
do valor  da  hemoglobina  e da  velocidade  de  sedimentac¸ão  (OR  1,36;  95%  CI  1,08-1,72;  p  = 0,01)
e da  terapêutica  biológica  (OR  1,19;  95%  CI  1,03-1,37;  p  =  0,017).  Para  um  valor  de  corte  de
RDW de  16%,  a  especificidade  e  o valor  preditivo  negativo  de CDAI≥ 150  foram  de  88%  e  86%,
respetivamente.
Conclusão:  Neste  estudo,  o valor  do RDW  demonstrou  ser  um  marcador  independente  e rel-
ativamente  específico  da  atividade  da  doenc¸a  de Crohn.  Estes  resultados  poderão  contribuir
para a  aplicac¸ão  deste  parâmetro  simples,  na prática  clinica  diária,  visando  auxiliar  decisões
terapêuticas.
© 2015  Sociedade  Portuguesa  de Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Crohn’s  disease  (CD)  is  a chronic  inflammatory  bowel  dis-
ease  (IBD)  characterized  by  a  relapsing-remitting  clinical
behavior.1 For this  reason,  the assessment  of  the severity
of  IBD  and  the  monitoring  of  disease  activity  are  important
issues.2
Currently,  endoscopy  with  biopsy  is  considered  the  gold
standard  for  the evaluation  of  mucosal  inflammation.2,4
However,  endoscopy  is  invasive  and requires  good bowel
cleansing,  a  procedure  that  is poorly  accepted  by  patients
and  potentially  harmful.1,2 Therefore,  CD  activity  index
(CDAI)  is  still  accepted  to  grade  CD activity  by  inter-
national  guidelines,  namely  European  Crohn’s  and  Colitis
Organization  (ECCO).  Despite  being based mainly  in clinical
parameters,  it remains  the principal  index  for evaluating  CD
patients’  outcomes  in clinical  studies.  Clinical  remission  is
accepted  as  a  CDAI  of <150.3
To  improve  non-invasive  monitoring  of CD activity,
numerous  biomarkers  (e.g.  C-reactive  protein  (CRP),  eryth-
rocyte  sedimentation  rate  (ESR),  leukocyte  and platelet
counts,  albumin,  fecal  calprotectin  and lactoferrin)5 have
been proposed  but  few have  proven  to  be clinically  useful  in
IBD.1,6 Nevertheless,  CRP  has  been  included  as  an ancillary
test  to  monitor  CD activity  by  ECCO guidelines.3
Red  cell  distribution  width (RDW)  is  a quantitative  mea-
sure  of  variability  in the size  of  circulating  erythrocytes.7,8
It  is  routinely  measured  by  automated  hematology  ana-
lyzers  and  is  usually  reported  as  a component  of  the
complete  blood  count  (CBC),9 thus  not  implying  additional
costs.10,11 Until recently,  it was  used mainly  to  differen-
tiate  iron deficiency  anemia  from  thalassemia  trait.11,12
However,  in the last  years,  numerous  studies  have shown
that  a higher  RDW  is  associated  with  several  patho-
logic  conditions,  including  heart  failure,9 acute  coronary
syndrome,13 atherosclerosis,14 pulmonary  impairment,15 and
Documento descargado de http://www.elsevier.pt el 13/05/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
8  A.M. Oliveira  et  al.
venous  thromboembolism.16 Also, some  studies  have  sug-
gested  that  RDW may  be  an inflammatory  marker  for  IBD,
mainly  in an inpatient  setting.17,18
Since  RDW  is  easily  accessible  and  relatively  cheap,
understanding  its  prognostic  significance  in the  context  of
CD  could  be  useful  to  optimize  clinical  decisions.  Conse-
quently,  we  hypothesized  that RDW  may  be  a surrogate
marker  of  CD  activity,  not only  in an inpatient  setting,  but
also  in  an  outpatient  setting.  Accordingly,  the purpose  of  this
study  was,  firstly,  to  determine  whether  RDW is  associated
with  CDAI;  and,  secondly,  to  identify  a  possible  RDW  cutoff
with  clinical  applicability  for an  outpatient  setting.
2.  Materials and methods
2.1.  Design, setting,  and participants
This  was  a  cross-sectional  observational  study  performed  at
the  Gastroenterology  Department  of a large  district  hospital
(Prof.  Doutor  Fernando  Fonseca  Hospital,  Amadora,  Portu-
gal).
All  CD  patients  (ascertained  by  standard  clinical,  radio-
logical,  histological,  and endoscopic  criteria)3 observed  in
the  IBD  outpatient  clinic  between  January  1st  and  Septem-
ber  30th  2013,  with  laboratory  evaluation  up  to  2  months
before  the  clinic  visit  were  included  in the  study.  Patients
with  follow-up  at our  clinic  for  less  than  6  months,  with
laboratory  evaluation  done  more  than  2 months  before  the
clinic  visit,  or  with  lack  of  information  to  assess  CDAI  were
excluded  from  the  study.
2.2.  Variables  and primary  outcome
Specific  patients’  characteristics  considered  were  the  fol-
lowing:  age,  sex,  Montreal  classification  of CD,20 blood  cell
indices  (RDW,  hemoglobin,  mean  cellular  volume  (MCV),
leukocyte  (WBC)  and  platelet  (PLT)  counts),  inflammatory
biochemical  parameters  (CRP  and  ESR),  and  medication
related  to  CD. In our  Department,  CD  management  follows
ECCO  guidelines.21
Primary  outcome  was  defined  as  CD  activity  measured
by  CDAI.  This  index  is  a numerical  calculation  derived  from
the  sum  of  eight  items,  each  considered  after  adjustment
with  a  weighting  factor.  CDAI items  include:  number  of
liquid  or  very  soft  stools,  abdominal  pain  score,  general
wellbeing,  symptoms  related  to  CD  (arthritis  or  arthral-
gia,  iritis  or  uveitis,  mucocutaneous  lesions  (e.g.  erythema
nodosum,  pyoderma  gangrenosum,  aphthous  stomatitis),
anal  disease  (e.g.  fissure,  fistula),  external  fistula  (e.g.
skin,  bladder,  vagina),  fever  >37.8 ◦C), antidiarrheal  med-
ications  use, abdominal  mass,  47  minus  hematocrit  (males)
or  42  minus  hematocrit  (females)  and 1  − x  (1  −  body  weight
divided  by  a  standard  weight).19 Patients  who  had  CDAI ≥ 150
were  accepted  as  having  active  disease,  whilst  CDAI < 150
defined  clinical  remission.3
2.3.  Statistical  analysis
Continuous  variables  were  reported  as  mean  and  standard
deviation  (SD),  if normally  distributed,  or  median  and
interquartile  range  (IQR),  if non-normally  distributed.  Cate-
gorical  variables  were  reported  as  absolute  number  (n) and
proportion  (%).
Group  comparisons  of  continuous  variables  were  per-
formed  using  Student  t-test  or  Mann--Whitney  test,  as
appropriate.  2 test  or  Fisher’s  exact  test  were  used for
group  comparisons  of  categorical  variables.
Logistic  regression  was  used  to  study  associations  with
the  primary  outcome.  Selection  of  variables  for  multivari-
ate  analysis  was  based on  clinically  relevant  knowledge  and
univariate  comparisons  yielding  a  p  <  0.15.  A forward  step-
wise  process  was  used  for the selection  of  variables  to  be
included  in final  models.  Collinear  behavior  was  studied  and
corrected  where  applicable.  Models’  discriminative  ability
was  assessed  by  c-statistic.
A RDW  cutoff  point  with  clinical  utility  was  studied
through  analysis  of  the coordinate  points  of ROC  curve.  Sen-
sitivity,  specificity,  negative  predictive  value,  and  positive
predictive  value  were  calculated  for the selected  cutoff
point.
All  statistical  tests  were  two-sided  and  a  p < 0.05  was
considered  to  be  significant.
Statistical  analyses  were  performed  using SPSS®, version
20.0  (IBM,  New  York).
3.  Results
3.1.  Baseline  characteristics
During  the study  period  considered,  119  patients  were
included.  Females  comprised  56.3%  (n  =  67)  and  mean  age
was  47  years  (SD,  15.2  years).
According  to  the  Montreal  classification,20 the predomi-
nant  features  present  from  the onset  of disease  were  an age
between  17  and 40  years  (A2)  (n =  67;  56.3%); terminal  ileal
disease  location  (L1)  (n  =  62;  52%); and  non-stenosing  and
non-penetrating  disease  behavior  (B1)  (n = 66;  56%).  Perianal
disease  was  diagnosed  in 24%  (n  =  28)  of  patients.
Thiopurines  and anti-tumor  necrosis  factor-  (anti-TNF-
) drugs  were  in  use  by  40.3%  (n  =  48)  and  21%  (n  =  25),
respectively  (with  8.4%  (n = 10) patients  taking  both  drugs).
Baseline  characteristics  are depicted  in Table  1.
Anemia  (defined  as  hemoglobin  <13  g/dL  if male  gender;
or  hemoglobin  <12 g/dL  if female  gender)22 was  present  in
29.4%  (n  =  35)  of  patients.
The  median  RDW  was  14.0  (13--15);  the  median  CRP  was
1.0  mg/dL  (1.0--3.75)  and  mean  ESR  was  33  mm.
Concerning  CD  activity  measured  by  CDAI,  17%  (n  =  20)
of  CD  patients  had  active  disease  (CDAI  ≥  150)  whereas  83%
(n = 99)  were in  clinical  remission.
Ten  patients  with  CDAI  ≥  150  had  CRP  ≥  1.0  mg/dL.
3.2.  Univariate  analysis
In univariate  comparisons,  RDW  (14.5  (13--17)  vs  13  (13--14);
p  = 0.044),  and  anti-TNF- drugs  (40%  vs  17%;  p =  0.044)  were
the only factors  associated  with  CDAI  ≥  150.
Albeit  not  statistically  significant  associated  with  CDAI,
there  was  a trend  toward  association  between  age,  ileo-
colic  location,  perianal  disease and hemoglobin  value  and
active  disease  (Table  1).  The  other  variables  analyzed,  with
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Table  1  Overall  baseline  characteristics  and  univariate  comparisons  based  on  disease  activity  measured  by  CDAI.
n  (%),  mean  (SD),  or  median  (IQR)  CDAI  <  150  p-Value
Total  CDAI  ≥  150  (n  = 99)
(n = 119) (n  = 20)
Gender,  female  67  (56.3%)  13/20  (65%)  54/99  (54.5%)  0.39
Age, years  47  (15.2)  48  (15.3)  41  (14.2)  0.076
Age at  diagnosis,  years  36.49  (14.87)  32.3  (11.75)  37.35  (15.34)  0.168
<16 years  6 (5%)  1/20  (5%)  19/20  (95%)  1.0
17--39 67 (56.3%) 13/20  (65%) 7/20  (35%)  0.39
≥40 46  (38.7%) 6/20  (30%) 14/20  (70%) 0.38
Location, n (%)
Ileal  62  (52%) 8/20  (40%) 54/99  (55%) 0.24
Colonic 15  (13%)  2/20  (10%)  13/99  (13%)  1
Ileocolic 38  (32%)  10/20  (50%)  28/99  (28%)  0.06
Upper gastrointestinal  tract  16  (13%)  3/20  (15%)  13/99  (13%)  0.73
Behavior
Non-stenosing,  non-penetrating 66  (55%) 13/20  (65%) 53/99  (53%) 0.35
Stenosing  28  (24%) 3/20  (15%) 25/99  (25%)  0.32
Penetrating 25  (21%) 4/20  (20%) 21/99  (21%) 1
Perianal disease 28  (24%) 8/20  (40%) 20/99  (20%) 0.06
Therapeutic
5-ASA solely  34  (28.6%)  0 34/99  (34%)  0.001
Thiopurine 48  (40.3%)  10/20  (50%)  38/99  (38%)  0.33
Anti-TNF- drugs  25  (21%)  8/20  (40%)  17/99  (17%)  0.02
Laboratory values
RDW  (n  = 119)  14.0  (13--15)  14.5  (13--17)  13  (13--14)  0.044
RDW ≥  16  (n =  119)  18  (15.1%)  6/20  (30%)  12/99  (12%)  0.042
Hgb (g/dL)  (n =  119)  12.96  (1.9)  12.27  (1.8)  13.11  (1.9)  0.07
Anemia (n  = 119)  35  (29.4%)  8/20  (40%)  27/99  (27%)  0.26
MCV (fL)  (n  =  117)  89.4  (7.8) 88.9  (9.5)  89.56  (7.44)  0.73
PLT (uL)  (n  =  118)  286200.85  (102750.04)  298300.00  (91909.6)  283731.63  (105087.6)  0.57
WBC (uL)  (n =  119)  7344.66  (2849.9)  7490.35  (3636.03)  7315.2  (2685.38)  0.80
CRP (mg/dL)  (n  =  60)  1.0  (1.0--3.75)  1.0  (0--4.75)  1.0  (1.0--3.25)  0.69
ESR (mm)  (n  =  75)  33.44  (25.82)  33.92  (32.46)  33.35  (24.68)  0.95
n, frequency; SD, standard deviation; IQR, inter-quartile range; CDAI, Crohn’s disease activity index; RDW, red cell distribution width; Hgb,
hemoglobin; WBC, white blood cell count; PLT, platelet count; Anti-TNF-, anti-tumor necrosis factor-; ESR, erythrocyte sedimentation
rate; CRP, C-reactive protein.
Anemia was defined as hemoglobin <13 g/dL if male gender; or hemoglobin <12 g/dL if female gender.
a  special  focus  on  CRP  and  ESR,  were not significantly  dif-
ferent  between  patients  with  CDAI  <  150  and  patients  with
CDAI  ≥  150.
3.3.  Multivariate  analysis
In  multivariate  analysis,  after  adjusting  for  age and gender,
RDW  was  associated  with  CDAI  ≥  150.  In the sub-population
of  patients  without  anemia,  RDW  was  also  associated  with
CDAI,  even  after  adjusting  for age  and gender  (Table  2).
Subsequently,  in  order  to  better  study  the association  of
RDW  with  CDAI  ≥  150,  three  further  models  were  derived.
As  depicted  in  Table  3,  RDW  was  independently  and  consis-
tently  associated  with  CDAI  after  adjusting  for  hemoglobin
and  ESR  (Model  1),  or  ileocolic  and  perianal  disease  (Model
2),  or  anti-TNF-  therapy  (Model  3).
Finally,  through  analysis  of  coordinate  points  of ROC
curve,  the cutoff  16%  was  deemed  the best  in prognosti-
cating  active disease  (AUC  0.64:  95%  CI: 0.5--0.78);  inherent
sensitivity,  specificity,  negative  predictive  value,  and  posi-
tive  predictive  value  of 30%, 88%,  86%  and  33%,  respectively
(Fig.  1).
4. Discussion
In  this  transversal  study,  we  found  that  an  increase  in RDW,
a simple  parameter  that  is  reported  as  part  of  a  standard
complete  blood  count,  was  associated  with  the severity  of
Crohn’s  disease,  assessed  by  CDAI.
This  association  remained  consistent  after  adjustment
for  clinical,  laboratory  parameters  and  therapy  (age,
gender, disease  location,  perianal  disease,  hemoglobin  and
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Table  2  Independent  indicators  association  with  active  CD  by  multivariate  logistic  regression  analysis.
Indicator  CD patients  CD  without  anemia
OR (95%  CI) p-Value  OR  (95%  CI) p-Value
RDW  1.20  (1.03--1.39)  0.016  1.59  (1.10--2.31)  0.014
Gender 1.42  (0.50--4.05)  0.510  3.06  (0.6--15.6)  0.178
Age 0.97  (0.93--1.02)  0.065  0.99  (0.94--1.04)  0.614
Multivariate logistic regression analysis for RDW, gender, age, and hemoglobin.
RDW, red cell distribution width.
Table  3  Multivariate  logistic  regression  analysis  for  the association  between  RDW  and  CDAI.
Model  1  Model  2  Model  3
OR  (95%  CI)  p  OR  (95%  CI) p OR  (95%  CI)  p
RDW  1.36  (1.08--1.72) 0.01 1.18  (1.03--1.35) 0.017  1.19  (1.03--1.37)  0.017
ESR 0.99  (0.96--1.02) 0.38
Hemoglobin  1.04  (0.70--1.53) 0.85
Ileocolic  disease 2.09  (0.74--5.9) 0.165
Perianal disease 2.27  (0.77--6.69) 0.138
Biologic therapy  3.33  (1.13--9.78)  0.029
RDW, red cell distribution width; ESR, erythrocyte sedimentation rate OR, odds ratio; CI, confidence interval.
Model 1: 2  test  9 (degrees of freedom: 3); p = 0.030; area under ROC curve: 0.73 (95% CI: 0.58, 0.89); n = 75  patients.
Model 2: 2  test  11 (degrees of freedom: 3); p = 0.012; area under ROC curve: 0.71 (95% CI: 0.58, 0.84); n  = 119 patients.
Model 3: 2  test  10.5 (degrees of freedom: 2); p = 0.005; area under ROC curve: 0.70 (95% CI: 0.55, 0.84); n  = 119 patients.
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Figure  1  ROC curve  for  RDW  (the  area  under  the  curve  is 0.64,
p =  0.04).  ROC,  receiver  operating  characteristic.
erythrocyte  sedimentation  rate,  and  anti-TNF- drugs).
These  results  are in line  with  previous  recent  results.9,17,18,23
The  mechanisms  that mediate  the  relationship  between
high  RDW  values  and  increased  CD  activity  are still  unknown.
An  elevated  RDW  is  commonly  found when there  is a
nutritional  deficiency,  such  as  iron,  folate,  or  vitamin  B12
deficiency.24 Also,  conditions  that  cause  more  immature
cells  to  be released  into  the  bloodstream  (severe  blood  loss),
abnormal  hemoglobins  (e.g.  sickle  cell  anemia),  or  hemol-
ysis  can  also  modify  the shape  of red  blood  cells,  resulting
from  an increased  RDW.25 Also,  it has  been  demonstrated
that  a chronic  inflammatory  state  may  contribute  to  ineffec-
tive  erythropoiesis  causing  immature  erythrocytes  to  enter
the  circulation,  resulting  in elevated  RDW.  Several  mecha-
nisms  are believed  to  mediate  the relationship  between  the
chronic  inflammatory  state  and  ineffective  erythropoiesis
leading  to  elevated  RDW.26,27 Proinflammatory  cytokines  like
tumor  necrosis  factor- and  interleukin-6  may  hinder  ery-
thropoiesis  via direct  suppression  of  erythroid  precursors,
promotion of apoptosis  of  precursor  cells,  enhancement  of
erythropoietin  resistance  in the precursor  cell  lines  and
reduction  in bioavailability  of  iron  for  hemoglobin  synthe-
sis.  Higher  oxidative  stress  may  reduce  erythrocyte  life-span
and  thus  may  result  in anisocytosis  due  to  an increase  in the
proportion  of  circulating  premature  erythrocytes.26--28
The  majority  of  patients  observed  in the IBD outpatient
clinic  were  in clinical  remission,  assessed  by  CDAI.  Only  17%
were  considered  to  have  active  disease,  despite  the fact  that
45%  of  patients  had  complicated  CD,  defined  as  stricturing
or  penetrating  behavior.
One interesting  finding  was  that  median  CRP  value
was  1 mg/dL  both  in patients  in  clinical  remission  and in
patients  with  active disease,  which  is  near  the normal  value
(<0.3  mg/dL).  As  CRP  is  considered  an objective  marker
of  inflammation,5 the  low value  may  be explained  by  low
inflammatory  activity  despite  having  active  disease  accord-
ing  to  CDAI.
In  this  study,  we  analyzed  the  association  between  hema-
tological  parameters  (including  hemoglobin,  MCV, RDW,  PLT,
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and  WBC),  CRP,  and  ESR  with  CDAI.  Through  univariate  com-
parisons,  we  demonstrated  RDW  was  the only  laboratory
parameter  independently  associated  with  CDAI.
Multivariate  logistic  regression  analysis  revealed  that
RDW  was  associated  with  CDAI considering  all  patients
included  in  the study  (anemic  and  non-anemic  patients),
even  after  adjusting  for  demographic  data  (age  and gender).
These  results  were  similar  in the sub-population  of  patients
without  anemia,  which  is  an important  finding  that  is  not
completely  understood.
Song  et  al.17 reported  identical  results.  In their  study,
they  showed  RDW was  highly  correlated  with  disease  activity
in  non-anemic  patients  as well  as  anemic  patients  with  IBD.
In  the  study  performed  by  Cakal  et al.,23 it  was  also  found
that  RDW  was  significantly  elevated  in patients  having  active
IBD  compared  with  those  without  active  disease.
Furthermore,  hemoglobin  and  ESR,  ileocolic  and  perianal
disease,  and  anti-TNF- therapy  did  not considerably  mod-
ify  the  association  between  RDW  and  CDAI.  It  is  particular
relevant  the  fact  that  the association  between  RDW  and  CD
activity  was  independent  of  anti-TNF-  drugs.  We  do  think
this  finding  may  be  due  to  a  more  severe  disease  which  is
indeed  more  difficult  to  control.
These  results  are  in line  with  the ones  reported  by  Song
and  colleagues.17 In  multivariate  analysis,  after  adjusting
for  patient  demographics  and hematologic  parameters,  the
authors  showed  RDW  was  associated  with  CDAI  ≥  150.
Finally,  this  study  revealed  RDW cutoff  of 16%  had  high
specificity  and  negative  predictive  value  for  determining  the
disease  activity  in CD patients,  albeit  with  a low sensitivity.
The  low  positive  predictive  value  may  be  due  to the low
prevalence  of primary  outcome.
In the  study  performed  by  Yesil  et  al.,18 a RDW  cutoff
of  14.7  had  a sensitivity  of  45%  and  a specificity  of  96%  in
detecting  active  CD.  However,  in the Cakal  et  al.’s23 study
a  RDW  cutoff  of  14.1  showed  78%  sensitivity  and  only 63%
specificity  to  detect  active  CD.
4.1.  Strengths  and limitations
This  study  has some  limitations  that  may  be  referred.
First,  this  is  an  observational  study  performed  in one
hospital  only.  For  this reason,  it is  prone  to selection  bias
and  limited  generalization.  Second,  the  size  of  our  popula-
tion  with  active  disease  was  small due  to  the fact  that  all
patients  included  were  in  outpatient  setting.  Future  stud-
ies  with  a  larger  population  of  active  CD patients  will  allow
to  accurately  identify  the degree  of  RDW  increase  which
reveals  active  disease.  Third,  iron  status  was  not  determined
(which,  as  discussed  above,  may  influence  RDW values).
Strengths  of  this  study  include  the  fact that  all  patients
included  were  in outpatient  setting  and  association  between
RDW  and  CDAI was  adjusted  for  clinical  and  laboratory
parameters  that  are  relevant  in daily  clinical  practice.
Second,  RDW  is  routinely  measured  by  automated  hema-
tology  analysers  and  is  reported  as  a component  of  the
complete  blood.  Thus,  testing  RDW  is  easy  to  perform,
affordable  and  does  not  require  any  additional  costs.
If  in  future  of large  prospective  studies,  RDW  is  confirmed
to  be  an  accurate  parameter  for disease  activity  monitor-
ing,  this  could impact  positively  outpatient  IBP  patients’
surveillance  and decision  making.
5.  Conclusion
In  conclusion,  in this study  we demonstrated  RDW  was  asso-
ciated  with  the severity  of Crohn’s  disease,  assessed  by
Crohn’s  disease  activity  index.  The  RDW  cutoff  16%  showed
possible  clinical  applicability.
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